Therapeutics

Therapeutic
Radiopharmaceuticals

At NorthStar, we remain committed to our mission of providing patients global access to game-changing radiopharmaceuticals with commercial scale production of actinium-225 (Ac-225) and copper-67 (Cu-67) that have the potential to improve cancer treatment outcomes.

The Future of Treating Cancer Involves

RADIONUCLIDE
Therapy

We are helping to reimagine cancer therapy by producing radioisotopes used to treat cancer and other potential serious diseases.

CANCER TREATMENT
OPTIONS MATTER, SO

Why
NorthStar?

We’ve taken what we’ve learned from successfully producing and commercializing an environmentally preferable diagnostic radioisotope, molybdenum-99 (Mo-99) and are applying that same experience and expertise in developing novel targeted radioisotope therapy.

MEETING THE GLOBAL DEMAND FOR CANCER-FIGHTING RADIOTHERAPEUTICS
REQUIRES SCALABLE AND RELIABLE PRODUCTION OF

ACTINIUM-225

Using NorthStar’s electron-beam accelerator technology, we will have the ability to produce sufficient, scalable quantities of Ac-225 to fulfill the growing patient need for cancer therapy and other serious diseases.

COPPER-67

Our isotope production technology will allow us to produce commercial scale quantities of Cu-67, the therapeutic companion to Cu-64.

UNDERSTANDING THE EVOLVING PARADIGM OF CANCER TREATMENT REQUIRES EXPERTISE IN A MULTITUDE OF HEALTHCARE SPECIALITIES

SCIENTIFIC
ADVISORS

Our experienced team of subject matter experts is helping bring to light important ideas to help maximize success of this new option for the treatment of cancer and other serious diseases.

CANCER THERAPY
REIMAGINED™

Important clinical studies are underway using Actinium-225 and Copper-67 in patients with various types of cancers including prostate, lung, breast, colon, melanoma, lymphoma and neuroendocrine. NorthStar is proud to be at the forefront of making these promising radiotherapies a reality.